The Social, Material, and Temporal Effects of Monthly Extended-Release Buprenorphine Depot Treatment for Opioid Dependence: An Australian Qualitative Study

被引:9
|
作者
Lancaster, Kari [1 ,5 ]
Gendera, Sandra [2 ]
Treloar, Carla [1 ]
Rhodes, Tim [1 ,3 ]
Shahbazi, Jeyran [4 ]
Byrne, Marianne [4 ]
Degenhardt, Louisa [4 ]
Farrell, Michael [4 ]
机构
[1] UNSW Sydney, Ctr Social Res Hlth, Sydney, NSW, Australia
[2] UNSW Sydney, Social Policy Res Ctr, Sydney, NSW, Australia
[3] London Sch Hyg & Trop Med, London, England
[4] UNSW Sydney, Natl Drug & Alcohol Res Ctr, Sydney, NSW, Australia
[5] UNSW Sydney, Ctr Social Res Hlth, Goodsell Bldg, Sydney, NSW 2052, Australia
基金
澳大利亚国家健康与医学研究理事会;
关键词
extended-release buprenorphine depot; long-acting injectable buprenorphine; opioid pharmacotherapy; social effects; time; qualitative study; CRITICAL RACE THEORY; PUBLIC-HEALTH;
D O I
10.1177/00914509221140959
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Aims:This study examined the social, material and temporal effects of extended-release buprenorphine depot treatment (BUP-XR), among a group of participants commencing BUP-XR in Australia, and considered the situated potentials of these new opioid agonist treatment technologies.Methods:Using a longitudinal qualitative design, 36 participants (25 men, 11 women; mean age 44 years) were interviewed, with 32 followed-up, to generate accounts of BUP-XR experiences. Analysis was informed by sociological approaches which attend to the multiple effects of novel health interventions as they are put to use and made to work, with a focus on tracing change over time.Analysis:The shift from daily to monthly dosing altered how opioid agonist treatment was experienced, reconfigured participants' relationship to treatment, and affected the temporal patterns of participants' lives. Extending temporal relations released participants from short-term cycles of living and produced different forms of subjectivity, bringing about both transformation and loss. Monthly dosing, and a sense of normalcy characterized by absenting the routines and felt effects of drugs or treatment medications, potentiated a feeling of stability for many participants. For some, disrupting daily routines precipitated disconnection from treatment and social care relations. The transition from daily to monthly dosing required adaptation and new ways of engaging with treatment and care, with medication acting as a bridge to care without necessarily being the focal point.Conclusions:As BUP-XR treatment gains traction internationally, it will be important to attend to the multiple, and sometimes unexpected, effects this intervention makes in the social and material lives of clients. How choice, social connection, and care can be maintained to help secure BUP-XR's longer-term impact, and how clients can be supported to adjust to what is felt to be a new normal, will be considerations in future treatment delivery.
引用
收藏
页码:105 / 120
页数:16
相关论文
共 50 条
  • [1] Tinkering with care: Implementing extended-release buprenorphine depot treatment for opioid dependence
    Lancaster, K.
    Gendera, S.
    Treloar, C.
    Rhodes, T.
    Shahbazi, J.
    Byrne, M.
    Nielsen, S.
    Degenhardt, L.
    Farrell, M.
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2024, 126
  • [2] EXPERIENCES AND EFFECTS OF EXTENDED-RELEASE BUPRENORPHINE DEPOT TREATMENT: QUALITATIVE FINDINGS FROM THE COLAB STUDY
    Lancaster, Kari
    Gendera, Sandra
    Treloar, Carla
    Rhodes, Tim
    Shahbazi, Jeyran
    Byrne, Marianne
    Degenhardt, Louisa
    Farrell, Michael
    DRUG AND ALCOHOL REVIEW, 2021, 40 : S18 - S18
  • [3] Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence
    Farrell, Michael
    Shahbazi, Jeyran
    Byrne, Marianne
    Grebely, Jason
    Lintzeris, Nicholas
    Chambers, Mark
    Larance, Briony
    Ali, Robert
    Nielsen, Suzanne
    Dunlop, Adrian
    Dore, Gregory J.
    McDonough, Michael
    Montebello, Mark
    Nicholas, Thomas
    Weiss, Rob
    Rodgers, Craig
    Cook, Jon
    Degenhardt, Louisa
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2022, 100
  • [4] Buprenorphine Extended-Release Treatment for Opioid Use Disorder in the Postpartum Period
    Galati, Bridget M.
    Wenzinger, Michael
    Rogers, Cynthia E.
    Cooke, Emily
    Kelly, Jeannie C.
    OBSTETRICS AND GYNECOLOGY, 2023, 142 (05): : 1148 - 1152
  • [5] Initiation of Extended-release Depot Buprenorphine in a Patient Subject to a Community Treatment Order for Both Antipsychotic and Opioid Agonist Treatments
    Pidutti, Joel
    Cuperfain, Ari B.
    Solway, Eric
    Duff, Virginia
    Lurie, Erin
    JOURNAL OF ADDICTION MEDICINE, 2023, 17 (06) : 742 - 744
  • [6] Subcutaneous Extended-release Buprenorphine Depot Misdiagnosed as an Abscess Resulting in Incision and Drainage and Disruption of Opioid Use Disorder Treatment
    Gray, Jessica R.
    Kehoe, Laura G.
    Peckham, Alyssa M.
    Wakeman, Sarah E.
    JOURNAL OF ADDICTION MEDICINE, 2023, 17 (02) : 227 - 229
  • [7] Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder
    Azar, Pouya
    Schneiderman, Hannah
    Barron, Henry
    Wong, James S. H.
    Meyer, Maximilian
    Newman-Azar, Dayyon
    Narimani, Matin
    Ignaszewski, Martha J.
    Mathew, Nickie
    Mullen, Rodney
    Krausz, Reinhard M.
    Maharaj, Anil R.
    ADDICTION SCIENCE & CLINICAL PRACTICE, 2024, 19 (01):
  • [8] Ninety-six week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a singlearm trial
    Farrell, Michael
    Shahbazi, Jeyran
    Chambers, Mark
    Byrne, Marianne
    Gholami, Jaleh
    Zahra, Emma
    Grebely, Jason
    Lintzeris, Nicholas
    Larance, Briony
    Ali, Robert
    Nielsen, Suzanne
    Dunlop, Adrian J.
    Dore, Gregory J.
    McDonough, Michael
    Montebello, Mark E.
    Weiss, Rob
    Rodgers, Craig
    Cook, Jon
    Degenhardt, Louisa
    DRUG AND ALCOHOL REVIEW, 2023, 42 : S72 - S73
  • [9] Comparative Effectiveness of Extended-Release Naltrexone vs. Buprenorphine for Opioid Dependence Treatment - NIDA CTN-0051
    Rotrosen, John
    NEUROPSYCHOPHARMACOLOGY, 2017, 42 : S60 - S61
  • [10] Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence
    Jackson, Heide
    Mandell, Kara
    Johnson, Kimberly
    Chatterjee, Debanjana
    Vanness, David J.
    SUBSTANCE ABUSE, 2015, 36 (02) : 226 - 231